Edgewise Therapeutics (EWTX) to Release Quarterly Earnings on Thursday

Key Points

• Edgewise Therapeutics (EWTX) is set to announce its Q2 2025 earnings on August 14th, with analysts predicting a loss of ($0.42) per share.
• The company's last earnings report showed a loss of ($0.43) per share, exceeding expectations and reinforcing an overall negative earnings outlook with forecasts of ($1) EPS for the current fiscal year.
• Several institutional investors have increased their stakes in EWTX, indicating a potential growth interest as analysts maintain a consensus rating of "Moderate Buy" with an average price target of $40.55.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Edgewise Therapeutics to post earnings of ($0.42) per share for the quarter.

Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.08. On average, analysts expect Edgewise Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Edgewise Therapeutics Trading Down 2.1%

Shares of Edgewise Therapeutics stock traded down $0.27 during trading hours on Friday, reaching $12.68. 568,056 shares of the company's stock were exchanged, compared to its average volume of 603,562. Edgewise Therapeutics has a 52-week low of $10.60 and a 52-week high of $38.12. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of -8.18 and a beta of 0.26. The company has a fifty day moving average of $14.02 and a 200-day moving average of $18.12.

Hedge Funds Weigh In On Edgewise Therapeutics

Several large investors have recently modified their holdings of EWTX. Goldman Sachs Group Inc. lifted its holdings in Edgewise Therapeutics by 5.7% in the first quarter. Goldman Sachs Group Inc. now owns 366,644 shares of the company's stock worth $8,066,000 after acquiring an additional 19,753 shares during the last quarter. Creative Planning lifted its holdings in Edgewise Therapeutics by 29.4% in the second quarter. Creative Planning now owns 16,910 shares of the company's stock worth $222,000 after acquiring an additional 3,837 shares during the last quarter. Strs Ohio bought a new position in Edgewise Therapeutics in the first quarter worth about $84,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Edgewise Therapeutics by 6.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,776 shares of the company's stock worth $963,000 after acquiring an additional 2,463 shares during the last quarter. Finally, Jones Financial Companies Lllp bought a new position in Edgewise Therapeutics in the first quarter worth about $47,000.

Analysts Set New Price Targets

A number of brokerages have weighed in on EWTX. Wedbush reissued an "outperform" rating and set a $43.00 price target on shares of Edgewise Therapeutics in a research note on Monday, April 21st. Guggenheim started coverage on Edgewise Therapeutics in a report on Wednesday, April 30th. They set a "buy" rating and a $41.00 price objective for the company. Raymond James Financial started coverage on Edgewise Therapeutics in a report on Wednesday, July 30th. They set a "strong-buy" rating and a $46.00 price objective for the company. Royal Bank Of Canada upped their price objective on Edgewise Therapeutics from $48.00 to $49.00 and gave the stock an "outperform" rating in a report on Friday. Finally, HC Wainwright started coverage on Edgewise Therapeutics in a report on Monday, June 30th. They set a "buy" rating and a $42.00 price objective for the company. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $40.64.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.